Clinical Perspective on Citizen Petition .

Uploaded on:
Category: Fashion / Beauty
Clinical Perspective on Citizen Petition. NDAC / PADAC Joint Meeting Robert J. Meyer, MD Director, DPADP CDER / FDA May 11th, 2001. Clinical Perspective. Important Considerations for OTC Switch : The ability of the consumer to self-diagnose and/or self-manage
Slide 1

Clinical Perspective on Citizen Petition NDAC/PADAC Joint Meeting Robert J. Meyer, MD Director, DPADP CDER/FDA May eleventh, 2001

Slide 2

Clinical Perspective Important Considerations for OTC Switch : The capacity of the customer to self-analyze as well as self-oversee Safety and adequacy for medication utilized as a part of OTC setting (i.e., without an "educated middle person")

Slide 3

Clinical Perspective These critical contemplations are frequently tended to by : OTC genuine utilize ponder; as well as Label cognizance concentrate on

Slide 4

Clinical Perspective Allegra, Claritin and Zyrtec are all antihistamines, all affirmed to treat unfavorably susceptible rhinitis FDA acknowledges hypersensitive rhinitis as a proper OTC sign, and FDA acknowledges antihistamines as suitable for OTC utilize FDA has built up fitting OTC naming for antihistamine items

Slide 5

Clinical Perspective Neither a real utilize think about nor a naming understanding study is fundamental for the OTC switch proposed FDA is not looking for guidance on : Allergic rhinitis as an OTC sign On the viability of Claritin, Zyrtec or Allegra in OTC setting

Slide 6

Clinical Perspective Focus of FDA clinical presentation is on security and how the wellbeing encounters bear on the choice for OTC accessibility FDA performed full security survey NDA information Post-promoting information (AERS) Other sources

Slide 7

Safety Presentation Elements of security presentation : NDA information Standard security information, cardiovascular wellbeing assessment, tranquilize collaborations Post-showcasing background Case Review, Epidemiology Focus for NDA on single fixing mixes AERS reports for incorporate all plans

Slide 8

Safety Presentation - Caveats Safety audit is not expected to be similar of the three specialists Safety audit won\'t endeavor to thoroughly contrast with OTC antihistamines Safety survey will characterize the wellbeing knowledge with these operators separately

Slide 9

Safety Presentation - Caveats Most authoritative wellbeing information are from NDA Post-advertising information offers less conclusive data about item security The utilization of the study of disease transmission assessments of AERS information can put post-promoting information in context, however is not complete

Slide 10

NDA Data Introduction Claritin (loratadine) endorsed for promoting April 12, 1993 Zyrtec (cetirizine) affirmed for promoting Dec. 8, 1995 Allegra (fexofenadine) endorsed for advertising July 25, 1996

Slide 11

NDA Safety Data Numbers of Patients Exposed Safety Experience in Clinical Trials Cardiac Safety (in vitro, creatures, human) Drug Interactions

Slide 12

NDA Safety Data Introduction Why the emphasis on cardiovascular security and medication tranquilize collaborations? Issues for Seldane (terfenadine): ECG/repolarization impacts (QT interim) Cases of threatening arrhythmias (TdP) Problem was clinically show because of medication collaborations Similar issues with Hismanal

Slide 13

NDA Safety Data Introduction Cardiac Investigation of this potential for another medication may incorporate : In vitro investigations of particle (K + ) stations and repolarization in separated cardiovascular muscle In vivo creature thinks about Clinical information e.g., high measurement and medication cooperation ponders, clinical observing in clinical trials

Slide 14

Claritin NDA Database In the NDA database for loratadine more than 90,000 patients uncovered Adverse occasion profile was reliable for an antihistamine given for unfavorably susceptible rhinitis No huge clinical wellbeing signals in unique NDA

Slide 15

Claritin NDA Database

Slide 16

Claritin NDA Database Somnolence was dosage related, with reporting of 10% with 20 mg QD, 12% with 40 mg QD Pediatric studies (6 - 11 years) demonstrated comparable AE profile Nervousness, hyperkinesia, wheezing and stomach torment likewise reported No huge security worries at the season of endorsement

Slide 17

Claritin Cardiac Safety In vitro testing (particle station, myocardial cells) was negative No QT or repolarization impacts recorded in creatures No noteworthy heart AE\'s seen in clinical trials (up to 160 mg) No clinically significant impact on QTc archived in clinical studies

Slide 18

Claritin Metabolic Considerations Loratadine metabolized by CYP3A4, 2D6 Drug connection examines with erythromycin, cimetidine and ketoconazole demonstrated some expansion in loratadine and desloratadine AUCs No clinically huge effect Renal and hepatic deficiency diminish freedom

Slide 19

Zyrtec NDA Database An Active metabolite of hydroxyzine Over 3900 patients were dealt with in clinical trials with Zyrtec Adverse occasion profile predictable with an antihistamine given for hypersensitive rhinitis

Slide 20

Zyrtec NDA Database

Slide 21

Zyrtec NDA Database Somnolence was dosage related Other AEs reported in kids at a rate higher than fake treatment in both doses: stomach torment, the runs, heaving sleepiness in youngsters 1.9% with 5 mg, 4.2% with 10 mg, fake treatment = 1.3% No huge security signals from unique NDA

Slide 22

Zyrtec Cardiac Safety In vitro testing (myocytes, particle stations) uncovered no impacts at applicable fixations No critical QT or repolarization impacts found in entire creatures No huge cardiovascular AE\'s seen in clinical trials, including 6 times the suggested measurement 1 of 4 security presentation concentrates on demonstrated an impact on the ECG 9.1 msec increment in QTC utilizing Bazett\'s remedy

Slide 23

Zyrtec Metabolic Considerations Renal discharge, the larger part unaltered No huge medication communications Renal weakness causes direct decline in leeway Hepatic impedance causes little impact on freedom

Slide 24

Allegra NDA Database Acid metabolite (dynamic) of terfenadine Over 2,353 patients presented to Allegra AE profile was of course given Allegra\'s medication class and signs contemplated

Slide 25

Allegra NDA Database

Slide 26

Allegra NDA Database Reporting of drowsiness not measurements related AE profile in Children furthermore appeared: migraines, incidental wounds, hack, fever, torment, otitis media and URIs No huge wellbeing signals in unique NDA

Slide 27

Allegra Cardiac Safety In vitro testing (particle stations, detached myocytes) demonstrated no confirmation of repolarization impacts No entire creature impacts even at high exposures No huge cardiovascular occasions reported in clinical trials No clinical ECG interim impacts seen, even at dosages up to 690 mg BID

Slide 28

Allegra Metabolic Considerations Fexofenadine negligibly metabolized Drug association contemplates indicated little increment in AUC No proof of vital changes in digestion system in exceptional populaces

Slide 29

NDA synopsis All three medications with adequate wellbeing in NDAs Work-up for heart impacts consoling Claritin with some medication tranquilize connections, however no evident clinical outcomes

Slide 30

POST-MARKETING Duration of showcasing will influence add up to quantities of reports Extent of utilization will influence add up to number of reports Heightened sensitivities may influence number of reports

Slide 31

POST-MARKETING Databases first broadly questioned up to 4/2000, upgraded for genuine occasions Overall, this evaluation demonstrates every one of the 3 medications to have a decent post-advertising security profile, however a couple signals seen No issues found in audit that would warrant reevaluation of endorsement

Slide 32

POST-MARKETING - OTC antihistamines Review of writing, AERS database additionally performed OTC antihistamines have satisfactory security profile CNS and anticholinergic AEs normal Rare instances of seizures, liver disappointment, genuine heart antagonistic occasions and other uncommon occasions have been noted

Slide 33

POST-MARKETING – Claritin 4081 Spontaneous AEs for all loratadine items Most regularly reported occasions were: Drug incapable Tachycardia Drug cooperation Insomnia Headache Sedation Palpitations Dermatitis Dizziness Nervousness

Slide 34

POST-MARKETING – Claritin Serious Cardiac occasions: 86 cases were checked on top to bottom Patient ages went from 2 to 87 years 38% of reports were for patients under 50 years of age Large greater part of cases happened in setting of frustrating variables

Slide 35

POST-MARKETING – Claritin Some hepatic terms are incorporated into posting of in Claritin naming 5 instances of hepatic disappointment in AERS database 3 of 5 had bewildering elements 2 of 5 not generally clarified, without clear causality

Slide 36

POST-MARKETING – Zyrtec 3096 Spontaneous AEs in database for cetirizine Most ordinarily reported occasions were: Drug inadequate Pruritus Sedation Drug Interaction Thrombocytopenia Asthenia Urticaria Headache Dermatitis Hypersensitivity

Slide 37

POST-MARKETING – Zyrtec Thrombocytopenia (low blood platelets): 1 case in NDA database 170 cases in the AERS database All yet 11 cases were not conceivably connected to cetirizine utilize Review of the 11 cases don\'t give a reasonable connection to the medication

Slide 38

POST-MARKETING – Zyrtec Seizures - 64 cases 26 cases reduced as unrealistically connected 38 cases were looked into top to bottom, 5 were not seizure occasions Ages ran from 3 to 79 years 21 new onset/12 previous seizure

Slide 39

POST-MARKETING – Zyrtec Serious cardiovascular occasions 37 cases were inspected top to bottom Patient ages extended from 3 to 80 years More than half under 50 years Majority of cases with jumbling highlights

Slide 40

POST-MARKETING – Allegra 1768 Spontaneous AEs for fexofenadine items Most usually reported occasions were: Drug ineffectual Sedation Nausea Insomnia Dizziness Palpitations Dermatitis Diarrhea Headache Dyspnoea

Slide 41

POST-MARKETING – Allegra Serious heart occasions 39 cases assessed Age go from 15 to 81 years Of the most genuine cases, the lion\'s share had an earlier heart history or potentially accompanying medications

Slide 42

POST-MARKETING – Allegra Seizures 17 of 30 cases were surveyed top to bottom ages ran from 22 to 80years old 9 patients with no past history 10 patients on medications known to bring about seizures 8 with dechallenge

View more...